Supporting Information for: New Use for CETSA: Monitoring Innate Immune Receptor Stability via Post-Translational Modification by OGT

Walter R. Drake[1,*], Ching-Wen Hou[1,*], Natasha E. Zachara[2], Catherine Leimkuhler Grimes[1,3]

[1]Department of Chemistry and Biochemistry, University of Delaware, Newark, DE 19716 USA, [2]Department of Biological Chemistry, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA [3]Department of Biological Sciences, University of Delaware, Newark, DE 19716 USA, [*]These authors contributed equally

Corresponding author: Catherine Leimkuhler Grimes, Department of Chemistry and Biochemistry, University of Delaware, Newark, DE 19716 USA; Tel, 302-831-2985; Fax, 302-831-6335; e-mail, cgrimes@udel.edu, ORCID: 0000-0002-0586-2879

A



B



Figure S1: Determination of [Thiamet-G] sufficient to shift *O*-GlcNAc levels in HEK293T-Nod2-Myc: Treatment of Nod2 over-expressing cells with Thiamet-G at

conditions used for NF-κB luciferase assay (100 nM, 4 hours). A) Global GlcNAc levels show a dramatic increase compared to DMSO when detected with GlcNAc antibody CTD110.6, demonstrating that these conditions sufficiently raise global *O*-GlcNAc levels. B) Immunoprecipitation of Nod2 over-expressing cells treated with Thiamet-G. Nod2-Myc over-expressing cells were treated with 100 nM Thiamet-G for 4 hours, immunoprecipitated using Myc antibody, and subjected to Western blot analysis using CTD110.6 antibody to detect GlcNAc. Cells treated with 100 nM Thiamet-G demonstrate an increase in GlcNAc levels on Nod2 compared to DMSO control and empty-vector, demonstrating that these conditions sufficiently raise Nod2 *O*-GlcNAc levels.